Romain Paoli-Lombardo

Dr. Romain Paoli-Lombardo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
IJInès Jacquet
Inès Jacquet
RPRomain Paoli-Lombardo
Romain Paoli-Lombardo
CCCaroline Castera-Ducros
Caroline Castera-Ducros
HPHugo Pomares
Hugo Pomares
SBSandra Bourgeade-Delmas
Sandra Bourgeade-Delmas
Nicolas PrimasNicolas Primas
Nicolas Primas
To explore the antileishmanial structure-activity relationships at position 2 of the 3-nitroimida-zo[1,2-a]pyridine scaffold, we developed a new synthetic method using Tetrakis(dimethylamino)ethylene (TDAE) and N-tosylbenzylimines. This original synthetic route was optimized to provide simple and reproducible access to diverse analogues functionalized at position 2. A library of 25 new derivatives was generated via efficient diversification at position 8 using nucleophilic aromatic substitution (SNAr) and Suzuki-Miyaura cross-coupling reactions. The 8-brominated analogues emerged as the most promising series, with six compounds exhibiting submicromolar activity against Leishmania infantum axenic amastigotes. Further substitution at position 8 with 4-pyridinyl or para-chlorothiophenol groups significantly decreased potency. The most active compound was also active on intramacrophagic amastigotes (half maximal inhibitory concentration (IC50) = 0.35 μM) without displaying any cytotoxicity on THP1 cell line (50 % cytotoxic concentration (CC50) > 100 μM). The reduction of its nitro group afforded an amino analogue, which retained antileishmanial activity (IC50 = 2.77 μM), indicating potential alternative mechanisms of action beyond nitro bioactivation. Despite its low solubility (<1 μM), this scaffold represents a novel and versatile entry point for antileishmanial drug discovery.

22 February 2024 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
Nicolas PrimasNicolas Primas
Nicolas Primas
CCCaroline Castera-Ducros
Caroline Castera-Ducros
RPRomain Paoli-Lombardo
Romain Paoli-Lombardo
CCChristophe Curti
Christophe Curti
FMFanny Mathias
Fanny Mathias
Vanelle PatriceVanelle Patrice
Vanelle Patrice
The Group for the Promotion of Pharmaceutical Chemistry in Academia (GP2A) held its 31st annual conference in August 2023 at the Faculty of Pharmacy of Aix-Marseille University, Marseille, France. There were 8 keynote presentations, 10 early career researcher oral presentations and 23 poster presentations. Among them, four awards were delivered, two for best oral communications and two for the best poster presentations.

13 October 2023 in Molbank
Verified
Journal Article
Open access
PDF file
OAOscar Leonardo Avendaño
Oscar Leonardo Avendaño
CCChristophe Curti
Christophe Curti
FMFabiana Maia Santos Urbancg Moncorvo
Fabiana Maia Santos Urbancg Moncorvo
YKYoussef Kabri
Youssef Kabri
SRSébastien Redon
Sébastien Redon
Vanelle PatriceVanelle Patrice
Vanelle Patrice
As part of our ongoing research into the antileishmanial properties of amidoxime derivatives, we report a preliminary assessment of the antiparasitic properties of a novel compound, diethyl (5-benzyl-2-(4-(N′-hydroxycarbamimidoyl)phenyl)-5-methyl-4,5-dihydrofuran-3-yl)phosphonate. This compound was evaluated in vitro for the first time against the promastigote form of Leishmania amazonensis. Compounds containing both amidoxime and phosphonyl functional groups in dihydrofuran scaffolds are relatively rare, despite the extensive study of this heterocycle in various biological applications. Therefore, this work makes a valuable contribution to the fight against Leishmania spp. as a neglected disease. The cyclized 4,5-dihydrofuran intermediate scaffold was obtained via a three-step synthetic route that had previously been developed for accessing other derivatives, including the sulfone moiety. This synthesis was performed using a manganese-based free radical oxidative method under microwave irradiation. The intermediary 4,5-dihydrofuran, which included a nitrile group, tolerated the subsequent reaction with hydroxylamine hydrochloride, resulting in the formation of the target product. The target compound showed moderate activity in vitro against the promastigote form of L. amazonensis (IC50 = 91.1 µM).

14 November 2024 in Molbank
Verified
Journal Article
Open access
PDF file
IJInès Jacquet
Inès Jacquet
RPRomain Paoli-Lombardo
Romain Paoli-Lombardo
CCCaroline Castera-Ducros
Caroline Castera-Ducros
Vanelle PatriceVanelle Patrice
Vanelle Patrice
Nicolas PrimasNicolas Primas
Nicolas Primas
In the context of our ongoing studies on 3-nitroimidazo[1,2-a]pyridine derivatives as potent antileishmanial compounds, we isolated a new unexpected compound from the spontaneous cycloaddition of N-[2-(8-bromo-6-chloro-3-nitroimidazo[1,2-a]pyridin-2-yl)-1-(4-chlorophenyl)ethyl]-4-methylbenzenesulfonamide. The molecular structure was fully characterized by using 1H and 13C NMR, X-ray crystallography, and HRMS.

7 April 2026
Verified
Thesis
Closed access
RPRomain Paoli-Lombardo
Romain Paoli-Lombardo
Les kinétoplastidés sont des protozoaires flagellés responsables de maladies tropicales négligées, pouvant être potentiellement mortelles chez l’Homme, telles que la leishmaniose viscérale (L. donovani et L. infantum), la trypanosomiase humaine africaine (T. brucei) ou la maladie de Chagas (T. cruzi), et pour lesquelles les traitements actuellement disponibles présentent des limitations. Ces dernières années, un regain d’intérêt est porté aux molécules anti-infectieuses nitroaromatiques, à l’image du fexinidazole. L’activité anti-kinétoplastidés de ces composés résulte de leur bioactivation sélective par des nitroréductases parasitaires, conduisant à la formation d’espèces réactives toxiques pour le parasite. Deux hits antileishmaniens et deux hits anti-Trypanosoma, substrats des nitroréductases parasitaires de type 1, ont été précédemment décrits en série 3-nitroimidazo[1,2-a]pyridine. Ces travaux de thèse portent sur la synthèse et l’étude des relations structure-activité de cent-trois dérivés originaux, dont soixante-et-un dérivés sont fonctionnalisés en positions 2, 6 et 8 du pharmacophore 3-nitroimidazo[1,2-a]pyridine, et trente-cinq dérivés sont fonctionnalisés en positions 5 ou 7, via des réactions de SN2, SNAr, ou de couplages pallado-catalysés. Deux dérivés en série 3-nitroimidazo[1,2-b]pyridazine et cinq dérivés 5-nitroimidazoles sont obtenus par miodification structurale. Ainsi, deux nouveaux hits ont été identifiés en série 3-nitroimidazo[1,2-a]pyridine, un premier antileishmanien, et un second anti-Trypanosoma, possédant tous deux de meilleurs paramètres pharmacocinétiques et physicochimiques que les hits précédents.

4 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RPRomain Paoli-Lombardo
Romain Paoli-Lombardo
VAVincent Arcani
Vincent Arcani
DDDelphine Dazan
Delphine Dazan
CCCaroline Castera-Ducros
Caroline Castera-Ducros
MEMarie-Anne Esteve
Marie-Anne Esteve
PRPascal Rathelot
Pascal Rathelot
In pediatric practice, nalbuphine hydrochloride can be administered by continuous infusion through a multiport manifold or Y-site connection over 24 h in a 60 mL polypropylene syringe unprotected from light at concentrations ranging from 52.1 µg.mL-1 to 333.3 µg.mL-1 in normal saline (NS). To limit the need for multiple injections, nalbuphine hydrochloride may be co-administered with other drugs. Its stability and compatibility were already studied at concentration ranges equal or higher than 1.0 mg.mL-1. However, when nalbuphine hydrochloride needs to be diluted for a pediatric administration its stability in NS over 24 h of light exposure at ambient temperature and its compatibility with other drugs have never been studied before. A novel chromatographic method using high-performance liquid chromatography (HPLC) was validated by the International Council for Harmonisation (ICH) Q2 (R1) guidelines. The stability of nalbuphine hydrochloride and the appearance of degradation products under five experimental conditions (light, heat, oxidation, basicity, and acidity) were monitored by HPLC-UV for 24 h at ambient temperature at three concentrations administered in pediatric departments (52.1 µg.mL-1, 166.7 µg.mL-1 and 333.3 µg.mL-1). The physical compatibility of nalbuphine hydrochloride with 1:1 (v/v) mixtures of selected drugs used in pediatrics was evaluated by visual inspection and with a 10 µm and 25 µm sub-visible particle counter. Our nalbuphine hydrochloride quantification method has been validated and was stability-indicating. The stability of nalbuphine hydrochloride and the forced degradation assay (light, heat, oxidation, basicity, and acidity) studied for the three concentrations of nalbuphine hydrochloride diluted in 48 mL of NS and stored in a 60 mL polypropylene syringe unprotected from light were compliant for at least 24 h at ambient temperature. Nalbuphine hydrochloride in NS was found to be compatible with several drugs, but was incompatible with furosemide and amphotericin B. Nalbuphine hydrochloride can be administered in pediatric practice using a syringe pump for 24 h. However, drug-drug incompatibilities need to be considered when it is administered through a multiport manifold or Y-site connection.